Stock GNRO GENEURO SA
Add to a list
To use this feature you must be a member
Log inSign up

GeNeuro SA Share Price

Equities

GNRO

CH0308403085

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 12:30:07 26/04/2024 pm IST 		5-day change 1st Jan Change
1.43 EUR 0.00% Intraday chart for GeNeuro SA 0.00% +31.19%
20/03 Geneuro SA Announces Appointments of Board of Directors CI
02/02 GeNeuro: share price falls after private placement CF

Financials

Sales 2023 * - Sales 2024 * 28.2M 30.15M 2.51B Capitalization 42.32M 45.25M 3.77B
Net income 2023 * -11M -11.76M -981M Net income 2024 * 1M 1.07M 89.18M EV / Sales 2023 * -
Net Debt 2023 * 13M 13.9M 1.16B Net Debt 2024 * 7.9M 8.45M 705M EV / Sales 2024 * 1.78 x
P/E ratio 2023 *
-3.33 x
P/E ratio 2024 *
47.7 x
Employees 19
Yield 2023 *
-
Yield 2024 *
-
Free-Float 73.47%
More Fundamentals * Assessed data

Chart GeNeuro SA

Dynamic Chart

Latest news about GeNeuro SA

Geneuro SA Announces Appointments of Board of Directors CI
GeNeuro: share price falls after private placement CF
GeNeuro Raises EUR5 Million from Share Issue MT
GeNeuro appoints new Chief Medical Officer CF
Geneuro Sa Announces Executive Changes CI
GeNeuro: Citigroup Global Markets Ltd crosses the 5% threshold CF
GeNeuro: positive opinion for continuation of trial CF
GeNeuro's Mid-stage Study for Post-COVID Symptoms Therapy Gets Medical Committee's Nod MT
Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications CI
GeNeuro Finalizes Patient Enrollment in Early-stage Trial of Long-COVID Treatment MT
GeNeuro: end of recruitment for Covid long trial CF
GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024 CI
GeNeuro and Verily Collaborate to Advance Long-COVID Research CI
GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
GeNeuro in Collaboration with Heinrich-Heine University Announce Publication in PNAS of Results from their Joint Research on Role of HERV-W in MS CI
More news

Press releases GeNeuro SA

GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting BU
GeNeuro - Independent Data Monitoring Committee recommends continuing the trial evaluating temelimab in Long COVID without any modifications AQ
GeNeuro : Investor Presentation October 2023 PU
GeNeuro : Half yearly financial reports and audit reports/limited reviews / Half yearly financial report PU
GeNeuro Reports 2023 Half-Year Results and Provides Corporate Update AQ
More press releases

News in other languages on GeNeuro SA

Les actionnaires de GeNeuro approuvent l’ensemble des résolutions proposées à l’Assemblée Générale Extraordinaire du 18 mars 2024
GeNeuro : le titre chute après un placement privé
SMALL & MIDCAPS : c'est parti pour Pluxee !
Amazon et Meta pour faire oublier Apple
Coil : Publicis, Quadient, Verimatrix... les valeurs à suivre aujourd'hui à Paris -
More news

Quotes and Performance

Current month+3.62%
1 month+10.00%
3 months+13.49%
6 months+17.21%
Current year+31.19%
More quotes

Highs and lows

1 week
1.42
Extreme 1.42
1.44
1 month
1.30
Extreme 1.3
1.53
Current year
1.05
Extreme 1.05
1.70
1 year
0.94
Extreme 0.94
1.99
3 years
0.94
Extreme 0.94
5.28
5 years
0.94
Extreme 0.94
6.28
10 years
0.94
Extreme 0.94
13.72
More quotes

Managers and Directors - GeNeuro SA

Managers TitleAgeSince
Jesús Martin-Garcia CEO
 Chief Executive Officer 62 01/06/01
Hervé Perron FOU
 Founder 66 01/06/01
Miguel Payró DFI
 Director of Finance/CFO 62 01/15/01
Members of the board TitleAgeSince
Philippe Archinard BRD
 Director/Board Member 63 27/21/27
Michel Dubois BRD
 Director/Board Member 81 16/08/16
Gordon Francis BRD
 Director/Board Member 75 17/15/17
More insiders

Quotes

Date Price Change Volume
26/24/26 1.43 0.00% 1
25/24/25 1.43 0.00% 2,279
24/24/24 1.43 0.00% 2,305
23/24/23 1.43 -0.35% 6,743
22/24/22 1.435 +0.35% 901

Real-time Euronext Paris, April 26, 2024 at 12:30 pm IST

More quotes

Company Profile

GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.
Sector
Biotechnology & Medical Research
Calendar
29/04/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.43 EUR
Average target price
4 EUR
Spread / Average Target
+179.72%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENEURO SA Stock GeNeuro SA
+31.19% 45.18M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GNRO Stock